Sex differences in the efficacy of cardiovascular and metabolic therapeutics on the incidence of dementia
- 주제(키워드) Treatments for dementia , Risk factor for dementia , Prevention of dementia , Sex differences
- 주제(DDC) 615.58
- 발행기관 아주대학교 글로벌제약임상대학원
- 지도교수 정이숙
- 발행년도 2024
- 학위수여년월 2024. 2
- 학위명 석사
- 학과 및 전공 글로벌제약임상대학원 글로벌제약임상약학과
- 실제URI http://www.dcollection.net/handler/ajou/000000033630
- 본문언어 영어
- 저작권 아주대학교 논문은 저작권에 의해 보호받습니다.
초록/요약
Sex differences in the efficacy of cardiovascular and metabolic therapeutics on the incidence of dementia Dementia is a clinical syndrome marked by a gradual decline in cognitive and functional abilities. Unfortunately, it remains an incurable condition, with conventional interventions, both pharmacological and non-pharmacological, demonstrating limited effectiveness, primarily in slowing down its progression. Given the absence of effective therapeutics for dementia, there is a crucial emphasis on identifying and preventing controllable risk factors. Specifically, cardiovascular and metabolic diseases have emerged as notable contributors to dementia development, underscoring the importance of managing and preventing these risk factors to avert the condition's onset. Moreover, a growing body of evidence suggests that sex-based factors may significantly influence disease pathogenesis, including dementia. Understanding these sex-specific differences is not only vital for optimizing drug efficacy tailored to both men and women but also for devising potential therapeutic strategies. In this study, I investigated gender differences in dementia therapeutics and examined the sex-specific efficacy variations of therapeutics targeting dementia risk factors with the aim of preventing the onset and progression of dementia. Keywords: Treatments for dementia, Risk factor for dementia, Prevention of dementia, Sex differences
more목차
Ⅰ. INTRODUCTION · 1
A. Treatments for dementia 1
B. Risk factor for dementiastress · 1
C. Sex-specific differences 2
D. Aims of study 2
Ⅱ. Sex Differences in the Efficacy of Dementia Therapeutics · 3
A. Cholinesterase inhibitors (ChEIs) 3
B. N-methyl-d-aspartate (NMDA) receptor antagonist 6
C. Anti- Aβ monoclonal antibodies (mAbs) · 7
ⅡI. Sex Differences in the Efficacy of Dementia Risk Factor Therapeutics 11
A. Cardiovascular Disease Therapeutics · 11
1. Antihypertensive Drugs 11
2. Antithrombotic Drugs · 14
3. Anticoagulants 16
B. Metabolic Disease Therapeutics · 19
1. Dyslipidemia Drugs 19
2. Antidiabetic Drugs 20
3. Anti-obesity Drugs 23
4. Gout Drugs 24
IV. CONCLUSION 27
REFERENCES 28
